OAB-051: Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed Multiple Myeloma (NDMM)
Titel:
OAB-051: Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed Multiple Myeloma (NDMM)
Auteur:
Costa, Luciano Chhabra, Saurabh Medvedova, Eva Dholaria, Bhagirathbhai Schmidt, Timothy Silbermann, Rebecca Godby, Kelly Dhakal, Binod Bal, Susan Giri, Smith D’Souza, Anita Cornell, Robert Hardwick, Pamela Omel, James Hari, Parameswaran Callander, Natalie S.